Team Hewins LLC Makes New $532,000 Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Team Hewins LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,573 shares of the biopharmaceutical company’s stock, valued at approximately $532,000.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Morgan Stanley grew its stake in Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after buying an additional 158,794 shares during the last quarter. Norges Bank bought a new position in Gilead Sciences during the 4th quarter valued at about $1,301,624,000. Northern Trust Corp lifted its holdings in Gilead Sciences by 3.5% during the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after purchasing an additional 504,475 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Gilead Sciences by 3.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 9,783,195 shares of the biopharmaceutical company’s stock valued at $792,547,000 after purchasing an additional 287,080 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after acquiring an additional 87,482 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.8 %

NASDAQ GILD traded down $0.55 during trading hours on Friday, reaching $65.62. The company’s stock had a trading volume of 3,779,889 shares, compared to its average volume of 7,212,433. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The firm has a fifty day simple moving average of $68.61 and a 200-day simple moving average of $74.64. The stock has a market cap of $81.75 billion, a P/E ratio of 181.81, a P/E/G ratio of 1.36 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.37 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.69%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GILD. Barclays dropped their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research note on Monday, April 29th. UBS Group reduced their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Maxim Group cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Royal Bank of Canada dropped their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research report on Friday, April 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $83.69.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.